Found 5900 clinical trials
Improving Survivorship Care for Older Adults After Chemotherapy
The researchers want to find out if older adults receiving a survivorship care plan followed by a geriatric assessment visit improves quality of life and satisfaction with care compared to receiving only a survivorship care plan for older adults who have completed chemotherapy for cancer treatment.
- 0 views
- 19 Feb, 2024
- 1 location
the Efficacy and Safety of 5-HT3 Receptor Antagonist Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy
To compare the efficacy and safety of megestrol acetate dispersible tablets combined with 5-HT3 receptor antagonist and dexamethasone triple antiemetic regimen and 5-HT3 receptor antagonist and dexamethasone combined antiemetic regimen in the control of CINV induced by hyperemetic chemotherapy.
- 0 views
- 19 Feb, 2024
- 1 location
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: Sacituzumab govitecan (IMMU-132) Pembrolizumab (Keytruda; MK-3475)
- 8 views
- 19 Feb, 2024
- 1 location
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old
Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
- 0 views
- 19 Feb, 2024
- 1 location
Ibrutinib + Venetoclax in Untreated WM
This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific MYD88 gene mutation. This research study involves an experimental drug combination of targeted therapies.
- 0 views
- 19 Feb, 2024
- 2 locations
Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma
This is a phase III randomized clinical trial of definitive radiotherapy plus EGFR blocker nimotuzumab versus radiotherapy plus cisplatin(CCRT) for nasopharyngeal carcinoma (NPC) patients with favorable response to induction chemotheray(IC), determining whether radiotherapy combined with nimotuzumab was non-inferior to CCRT and may provide new evidence for individualized comprehensive treatment of …
- 0 views
- 19 Feb, 2024
- 1 location
Pembrolizumab Plus Paclitaxel Cisplatin Followed by Surgery for Locally Advanced ESCC
The purpose of this study is to observe and evaluate the efficacy and safety of pembrolizumab plus paclitaxel, cisplatin followed by Da Vinci robot radical surgery for locally advanced esophageal squamous cell carcinoma.
- 0 views
- 19 Feb, 2024
- 1 location
Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma
To compare the effectiveness and toxicity of nedaplatin versus cisplatin in induction chemotherapy combined with concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma.
- 0 views
- 19 Feb, 2024
- 1 location
SBRT Dose Escalation for Reirradiation of Inoperable Lung Lesions
Prospective phase I study to evaluate the maximum tolerated dose (MTD) of SBRT for thoracic re-irradiation. Dose limiting toxicity will be pneumonitis G3. The potential advantage of the dose escalation planned in this study is the delivery of an ablative dose to radically treat patients with inoperable local relapse, without …
- 0 views
- 19 Feb, 2024
- 1 location
COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID)
COVID-19 infection has spread worldwide causing several deaths in few months Convalescent Plasma from COVID 19 donors has shown huge activity in small series from Chinese patients and currently many centers from USA and the European Union are assessing its use looking to avoid mortality and prolonged hospitalizations COVID-19-related
- 0 views
- 19 Feb, 2024
- 1 location